Login
Register
Forum
News
Jobs
Contact us
Belgian Hematological Society
Home
About BHS
Board Members
Secretarial offices
Membership
Benefits
Application
Members
Hematology centers
Statutes
Clinical
Clinical trials
Inventory of trials in Belgium
BHS trials
Regulatory
Calculators
Medical need programs
Rituximab
Valganciclovir
Bendamustine hydrochloride
Registries
Guidelines
Drugs
Education
BHS courses
Travel grants
Training
Belgian Journal of Hematology
On-line resources
Committees
Lymphoma
Members
Agenda
Minutes
Guidelines
Publications
Studies
News
MDS
Members
Agenda
Minutes
Guidelines
Publications
Studies
News
MPN
Members
Agenda
Minutes
Guidelines
Publications
Studies
News
Myeloma
Members
Agenda
Guidelines
Minutes
Publications
Studies
News
Red cells
Members
Agenda
Minutes
Guidelines
Publications
Studies
News
Transplant
Members
Agenda
Minutes
Guidelines
Publications
Studies
News
JACIE
Members
Agenda
Minutes
Guidelines
Publications
Studies
News
Regulatory Affairs
MDP-B
Members
Agenda
Minutes
Guidelines
Publications
Studies
News
Nurses
Members
Agenda
Minutes
Guidelines
Publications
Studies
News
Non-BHS committees
Meetings
International Meetings
Training Course on rare anaemias
National meetings
General annual meetings
Post-ASH meetings
National JACIE Meeting-day
Nurse Program at the GAM
Links
Scientific societies
Scientific groups
Regulatory & Government
Transplantation
Drugs
Calculators
Clinical Trials
Guidelines
Online resources
Journals
Journals-database
Journals-specific
Funding
Universities
Hospitals
Patient associations
Miscellaneous
Patients
Hematology centers
Patient associations
Disease information
Brochures
Follicular lymphoma
Home
›
Clinical
›
Medical need programs
›
Valganciclovir
Valganciclovir
Introduction letter
Order form
